{"id":"met-ir","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3-5","effect":"Metallic taste"},{"rate":"10-30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:28:18.892103","_dailymed":{"setId":"9bcce2ee-42c2-29cf-e053-2a95a90a3639","title":"HANGOVER HELP (AGARICUS MUSC., ARSENICUM ALB., BISMUTHUM METALLICUM, BRYONIA, CAPSICUM, CARBO VEG., GLONOINUM, IPECAC., IRIS VERSICOLOR, LAUROCERASUS, LYCOPODIUM, MEZEREUM, NUX VOM., PULSATILLA, RANUNC. BULB. , THERIDION, VERATRUM ALB., ZINC. MET., ZINGIBER, CHAMOMILLA, PASSIFLORA, VALERIANA) LIQUID [NEWTON LABORATORIES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and improving peripheral glucose uptake and utilization. The immediate-release formulation allows for rapid absorption and onset of action compared to extended-release formulations. It does not stimulate insulin secretion, making it suitable for use across a range of glycemic control states.","oneSentence":"Met IR is a formulation of metformin immediate-release that reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:00:43.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"_fixedFields":["pubmed(18)"],"trialDetails":[{"nctId":"NCT07066670","phase":"NA","title":"Strain Counterstrain and Muscle Energy Technique in Patients of Knee Osteoarthritis","status":"COMPLETED","sponsor":"University of Lahore","startDate":"2024-03-15","conditions":"Stroke","enrollment":76},{"nctId":"NCT07022405","phase":"PHASE2","title":"Stratified Pharmacological Approaches for Regulating Circuit-Level Effects","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-08","conditions":"Depression - Major Depressive Disorder","enrollment":60},{"nctId":"NCT06215313","phase":"NA","title":"EMDR Versus Imagery Rescripting for Trauma-Related Intrusions","status":"ENROLLING_BY_INVITATION","sponsor":"Geestelijke Gezondheidszorg Eindhoven (GGzE)","startDate":"2025-01-28","conditions":"Stress Disorders, Post-Traumatic, Depression","enrollment":42},{"nctId":"NCT06533072","phase":"NA","title":"Infrared LED Lighting Application and Wound Healing","status":"RECRUITING","sponsor":"Ardahan University","startDate":"2024-06-15","conditions":"Cholecystectasia, Wound Heal, Scar","enrollment":80},{"nctId":"NCT06213870","phase":"","title":"Screening of Endovascular Thrombectomy With MRI in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tianjin Huanhu Hospital","startDate":"2022-08-01","conditions":"Fluid-attenuated Inversion Recovery Sequence Vascular Hyperintensity-diffusion-weighted Imaging Mismatch(FVH-DWI Mismatch), Image Evaluation, Endovascular Thrombectomy","enrollment":309},{"nctId":"NCT05724849","phase":"PHASE2","title":"Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2023-08-01","conditions":"Head and Neck Cancer, Depression","enrollment":""},{"nctId":"NCT05947669","phase":"PHASE3","title":"Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2023-08-22","conditions":"Colitis","enrollment":195},{"nctId":"NCT05612282","phase":"","title":"The Impact of the Distribution of Adipose Tissue on the Occurrence of Metabolic Disorders and the Level of Cardiopulmonary Fitness","status":"COMPLETED","sponsor":"Medical University of Bialystok","startDate":"2016-11-11","conditions":"Obesity, Abdominal","enrollment":91},{"nctId":"NCT05151146","phase":"PHASE1","title":"A Phase 1 Study of ANJ900 Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Anji Pharma","startDate":"2021-10-15","conditions":"Healthy","enrollment":18},{"nctId":"NCT03343366","phase":"PHASE2, PHASE3","title":"Glycemic Control in T2DM Through Non-Surgical Periodontal Therapy","status":"COMPLETED","sponsor":"Dow University of Health Sciences","startDate":"2018-01-01","conditions":"Chronic Periodontitis, Type 2 Diabetes Mellitus","enrollment":150},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02526524","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2015-09","conditions":"Type 2 Diabetes Mellitus","enrollment":571},{"nctId":"NCT02291510","phase":"PHASE1","title":"Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2012-10","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT01677299","phase":"PHASE1, PHASE2","title":"Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2012-05","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT02221180","phase":"PHASE1","title":"Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-08","conditions":"Bioequivalence","enrollment":2},{"nctId":"NCT01537081","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections","status":"COMPLETED","sponsor":"Reckitt Benckiser LLC","startDate":"2011-09","conditions":"Acute Upper Respiratory Tract Infection","enrollment":2810},{"nctId":"NCT01459094","phase":"PHASE1","title":"Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT01463774","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Healthy","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"recentPublications":[{"date":"2025 Oct","pmid":"40828352","title":"Efficacy and Safety of Triple Fixed Dose Combination of Dapagliflozin + Sitagliptin + Metformin IR in Indian Patients with Type 2 Diabetes Mellitus: A Randomized, Phase 3 Study in Comparison with Dual FDC Sitagliptin + Metformin IR.","journal":"Advances in therapy"},{"date":"2022 Jun","pmid":"35535946","title":"Family Input for Quality and Safety (FIQS): Using mobile technology for in-hospital reporting from families and patients.","journal":"Journal of hospital medicine"},{"date":"2022 Feb 24","pmid":"35269415","title":"Enhanced Wild-Type MET Receptor Levels in Mouse Hepatocytes Attenuates Insulin-Mediated Signaling.","journal":"Cells"},{"date":"2022 Feb 1","pmid":"35120288","title":"Treating Insulin Resistance With Metformin as a Strategy to Improve Clinical Outcomes in Treatment-Resistant Bipolar Depression (the TRIO-BD Study): A Randomized, Quadruple-Masked, Placebo-Controlled Clinical Trial.","journal":"The Journal of clinical psychiatry"},{"date":"2021 Jul","pmid":"34350076","title":"Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves.","journal":"Cureus"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Met IR","genericName":"Met IR","companyName":"Elcelyx Therapeutics, Inc.","companyId":"elcelyx-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Met IR is a formulation of metformin immediate-release that reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}